FibroGen (FGEN) has a debt-to-equity ratio of -0.67, below the Healthcare sector average of 0.31.
Get informed when a big investor buys or sells
+ Follow-0.67
Debt-to-Equity ratio measures a company's financial leverage by comparing its total debt to shareholder equity. A lower D/E ratio generally indicates a more financially stable company with less risk.
As of the most recent data, FGEN shows a debt-to-equity ratio of -0.67. That is below the Healthcare sector average of 0.31. Scroll down for historical charts and peer comparison views.
The Healthcare sector average debt-to-equity ratio is about 0.31. FibroGen is at -0.67, which is lower that average. That is roughly 315.8% below the sector mean. Use the comparison chart on this page to see how FGEN stacks up against individual peers as well.
Investors watch FGEN's debt-to-equity ratio because it compresses price and fundamentals into one number that is easy to compare across companies and over time. FibroGen's latest reading is -0.67. Combining that with growth, ROE, and debt metrics usually beats relying on a single multiple.
Besides this debt-to-equity ratio page, Stockcircle has FibroGen's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect debt-to-equity ratio (currently -0.67) with ownership activity and broader fundamentals.
The Healthcare average debt-to-equity ratio is about 0.31, while FGEN is at -0.67. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.